Introduction
Hyperthermic isolated regional perfusion of the limb (ILP) is a technique which has the possibility to deliver high concentrations of chemotherapeutic agents to an extremity, whereas only low drug concentrates are reached in the systemic circulation. Since Luck introduced melphalan (L-phenylalanine mustard) in 1956 as an active agent to inhibit growth of malignant melanoma in mice, it has been the preferred agent in ILP for intransit metastases of melanoma. 1 Although ILP with melphalan is effective in the treatment of the patients with intransit metastases of melanoma, with a complete response rate of 50%, it has no effect in the adjuvant setting. [2] [3] [4] Newer drugs which might be more effective than melphalan in the treatment of melanoma by ILP have therefore been sought. Cisplatin is one of the most active drugs in cancer treatment, however it has serious dose-limiting toxicity such as neuro-, nephro-, and ototoxicity. 5 Therefore ILP with cisplatin was evaluated as an alternative to overcome these limitations of systemic treatment in the treatment of recurrent melanoma of the limb. However the effectiveness of cisplatin in the so called therapeutic perfusion setting and for local control of tumor growth for the treatment of locally advanced melanoma and sarcoma of the extremities with delayed excision is not impressive. [6] [7] [8] [9] [10] And the local neurological side effects of ILP with cisplatin in the perfused limb are still present in the form of a irreversible peripheral sensory and motor neuropathy. 7 Therefore in several institutions cisplatin was abandoned as a cytostatic agent in the perfusion setting.
There are however several other institutions that still use and advocate cisplatin in ILP. [11] [12] [13] Carboplatin is a second generation platinum analogue with similar efficacy in most tumors but with less neuro-, oto-and nephrotoxicity when compared to cisplatin when applied systemically. 14, 15 A feasibility study was initiated to study the effect of carboplatin, as an agent for ILP with respect to the local tumoricidal effect, as well as the local treatment morbidity.
Patients and Methods
Between November 1991 and February 1993 two patients (patient 1 and patient 2) with locally advanced recurrent and intransit metastases of melanoma of the lower 53 limb (Stage IIIA, MD Anderson staging) and one patient (patient 3) with a locally advanced primary irresectable soft tissue sarcoma of the lower limb participated in a feasibility study of ILP with carboplatin. None of the patients had distant metastases at time of the perfusion. Patients were treated with intent of preserving the affected extremity. The maximum follow up period was 95 months. Patient data are summarized in Table 1 . Since the systemic dosage of carboplatin used clinically is 4 times the cisplatin dosage, a fourfold higher dose compared to cisplatin was used for the limb perfusion. 5, 16 Based upon an earlier dose finding study where a maximum dose of cisplatin of 30 mg/L limb volume was used in ILP, an initial carboplatin dosage was chosen of 125 mg/L limb volume. 7 17 All patients were operated under general anaesthesia. After a skin incision, the iliac, femoral or popliteal vessels were exposed and collateral vessels were clipped. The patients were heparinized (3.3mg/kg body weight) and catheters were inserted in the artery and vein, and both were connected to an extracorporeal circuit. The extremity was was approximately 500 ml/min. After 1 hour of perfusion, the extremity was flushed with 500 ml Isodex® in 0.9% NaCl and 250 ml red blood cell concentrate.
Both catheters were removed and the vessels were repaired. The heparin was then neutralized with protamine sulfate and a fasciotomy was performed to prevent a compartment syndrome. Before and during the perfusion, 10 ml perfusate samples were collected at 10 min intervals to determine the ultrafiltrated platinum (fPt) levels as previously extensively published. 19 The leakage into the systemic circulation was also determined by measuring the patients fPt plasma concentrations at the end of each perfusion procedure both before and after restoration of the circulation to the perfused limb and during the 7 days following ________________________________________ C h a p t e r I I I 55 the perfusion. For fPt perfusate elimination kinetics, data were subjected to logarithmic regression analysis (concentration = A.e -k.t ). The areas under the concentration vs. time curves (AUC) were calculated using the model independent trapezoidal rule and covers the perfusion period (t = 0 -60 min). 20 Tissue biopsies were taken for fPt determination in both melanoma patients at the end of the ILP, when the normal limb circulation was restored.
All three patients were followed up post operatively by history, physical examination, and routine blood counts and blood chemistry analysis were performed on a daily basis on days 1 -7, and 14 and 21 days postoperatively. Total serum protein and albumin was controlled one day preoperatively and postoperatively. Six weeks after perfusion electrodiagnostic evaluations (electromyogram (EMG) and nerve conduction study) were performed to investigate nerve toxicity of the carboplatin perfusion in patients 1 and 3.
Unfortunately patient 2 refused the neurological examination. The local limb perfusion toxicity was graded according to the criteria decribed by Wieberdink et al. 21 Eight weeks after perfusion, patient 3 was readmitted for a so called delayed resection of a locally advanced soft tissue sarcoma of the lower limb. The study was approved by the local Medical Ethical Committee of the Groningen University
Hospital and all patients gave informed consent.
Results
All three perfusions could be performed under standard perfusion conditions with minimal I 131 -albumin leakage (0-5%) ( Table 2 ) and without any acute systemic toxicity or morbidity. The local toxicity consisted in all 3 patients of a grade II toxicity of the perfused limb which is characterized by erythema, edema or loss of sensation which resolved spontaneously in all patients. 21 following the perfusion. Perfusion data and pharmacokinetic parameters are summarized in Table 1 and Table 3 
Discussion
Regional isolation perfusion was introduced to deliver large doses of cytotoxic drugs to the local tumor area while avoiding systemic toxicity. Melphalan is still the most frequently used antitumor drug in ILP for melanoma. 6, 8, 22, 23 Even with a high remission rate (80%), a great deal (50%) of the melanoma patients fail to achieve a durable complete response. 2,3,23 Therefore a search was initiated for alternative drugs or the application of combination of agents to be used in ILP.
Several cytostatic agents have been used besides melphalan, such as actinomycin D and DTIC (imidazole carboxamide). The feasibility of cisplatin in ILP has also previously been investigated by several institutions, but with conflicting results.
Some authors claim that the local severe toxicity and the equal or less effectiveness does not justify the use of cisplatin. [6] [7] [8] [9] [10] But there are also other institutions that still use and advocate the use of cisplatin in ILP. [11] [12] [13] Carboplatin, a second generation platinum compound, was attractive for clinical use because of its reduced nephro-, neuro-, and ototoxicity than cisplatin when administered systemically. 24 It differs in the molecular structure from cisplatin by replacing the two cis chloride atoms by 59 a cyclobutane dicarboxylate molecule. 5 Platinum co-ordination complexes inhibit tumor growth by their effects on DNA replication. Once bifunctionally bound to DNA, the mode of action of carboplatin is not different from cisplatin, but the platinum induced DNA lesions (DNA interstrand cross links) are formed at a slower rate with carboplatin compared to cisplatin. 16 There has only been one case report and one study in which carboplatin has been used for isolated limb perfusion. Nakayama et al. reported minimal side effects after perfusing 1 patient with 450 mg carboplatin for melanoma of the lower limb. 25 They found a complete clinical and histologic response of the tumor and in their follow up period of 10 months, no local recurrency was observed. This is in concordance with the findings of Ariyan et al. who performed ILP on 20 patients with carboplatin (400 mg/m 2 body surface area) and the results were found to be effective and with very low toxicity with a median follow up of 25 months. 11 Both studies however do not report on observed local neurotoxicity. In our study the carboplatin dosage was calculated on the limb volume and not on the body surface area, thus leading to a much larger carboplatin dosis administered (up to 4 times as much). This could possibly explain the enhanced neurotoxicity seen in this series.
Next to the search for new agents for ILP, different combinations of drugs are being investigated. The combination of tumor necrosis factor α (TNFα) and melphalan has been used for the local perfusion of recurrent melanoma of the limbs and for extremity sarcomas. [26] [27] [28] [29] [30] [31] Lienard et al. reported that the complete response rate for melanoma metastases increased to 80 -90% after the addition of TNFα to the perfusate, but with an increased risk of side effects. 31 The median disease free interval time did not increase with the addition of TNFα, making monotherapy with melphalan currently the drug of choice for ILP in melanoma. 23 For soft tissue sarcomas of the limbs the combination of TNFα and melphalan as perfusion agents has been proven to be effective in salvaging the affected limbs. 27, 28, 30 Results from a recent international multicenter study, showed that in 246 patients with irresectable soft tissue sarcoma a complete response rate of 28%, a partial response rate of 47% and 17% no change after perfusion with TNFα and melphalan was observed. Enabling delayed excision and preserving the extremity in a substantial number (71%) of perfused patients. 32 A combination of TNFα and cisplatin has been investigated by Bartlett et al. in peritoneal perfusion in the treatment of peritoneal carcinomatosis. 33 The results were disappointing because of an increased nephrotoxicity compared to cisplatin alone, rendering it unfeasible. A canine experimental study by van Ginkel et al.
also combined the drugs cisplatin and TNFα in ILP and tested this regimen 6 healthy dogs. 34 They observed an increased toxicity compared to ILP with cisplatin alone. Despite a sublethal systemic concentration of TNFα that leaked from the perfusion circuit, 3 dogs died within 24 hours of ILP. Another dog developed a necrotic limb which the authors explained as an enhanced cytotoxic effect of cisplatin to the local tissues due to the addition of TNFα. Taking into account the before mentioned results between cisplatin and TNFα and considering the similarity between cisplatin and carboplatin, we do not warrant further investigation into the feasibility of the combination between carboplatin and TNFα.
The local neurotoxicity observed with ILP makes carboplatin an unattractive alternative agent for ILP. However, compared to the before mentioned studies of 61 Nakayama 25 and Ariyan 11 the patients in this study received a higher dose of carboplatin which could account for the observed neurotoxicity.
